Cited by 792Hormonal and reproductive studiesBone health and osteoporosis researchGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

Katznelson, L, Finkelstein, J S, Schoenfeld, D A, Rosenthal, D I, Anderson, E J, Klibanski, A·1996·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jcem.81.12.8954042

Open this paper in CoChat — free account

Abstract

Acquired hypogonadism is being increasingly recognized in adult men. However, the effects of long term testosterone replacement on bone density and body composition are largely unknown. We investigated 36 adult men with acquired hypogonadism (age, 22-69 yr; median, 58 yr), including 29 men with central hypogonadism and 7 men with primary hypogonadism, and 44 age-matched eugonadal controls. Baseline evaluation included body composition analysis by bioimpedance, determination of site-specific adipose area by dual energy quantitative computed tomography scan (QCT) of the lumbar spine, and measurements of spinal bone mineral density (BMD) using dual energy x-ray absortiometry, spinal trabecular BMD with QCT, and radial BMD with single photon absorptiometry. Percent body fat was significantly greater in the hypogonadal men compared to eugonadal men (mean +/- SEM, 26.4 +/- 1.1% vs. 19.2 +/- 0.8%; P < 0.01). The mean trabecular BMD determined by QCT for the hypogonadal men was 115 +/- 6 mg K2HPO4/cc. Spinal BMD was significantly lower than that in eugonadal controls (1.006 +/- 0.024 vs. 1.109 +/- 0.028 g/cm2; P = 0.02, respectively). Radial BMD was similar in both groups. Testosterone enanthate therapy was initiated in 29 hypogonadal men at a dose of 100 mg/week, and the subjects were evaluated at 6-month intervals for 18 months. During testosterone therapy, the percent body fat decreased 14 +/- 4% (P < 0.001). There was a 13 +/- 4% decrease in subcutaneous fat (P < 0.01) and a 7 +/- 2% increase in lean muscle mass (P = 0.01) during testosterone therapy. Spinal BMD and trabecular BMD increased by 5 +/- 1% (P < 0.001) and 14 +/- 3% (P < 0.001), respectively. Radial BMD did not change. Serum bone-specific alkaline phosphatase and urinary deoxypyridinoline excretion, markers of bone formation and resorption, respectively, decreased significantly over the 18 months (P = 0.003 and P = 0.04, respectively). We conclude that testosterone therapy given to adult men with acquired hypogonadism decreases sc fat and increases lean muscle mass. In addition, testosterone therapy reduces bone remodeling and increases trabecular bone density. The beneficial effects of androgen administration on body composition and bone density may provide additional indications for testosterone therapy in hypogonadal men.

Integrity signals

Registry

Crossref · 10.1210/jcem.81.12.8954042

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Measurement of Bone Mineral in vivo: An Improved Method
CAMERON, J. R., & Sorenson, J. A. (1963) · Science · doi:10.1126/science.142.3589.230 · Cited by 827
Effects of testosterone supplementation in the aging male.
Tenover, J. S. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.4.1400877 · Cited by 702
Risk factors for spinal osteoporosis in men
Seeman, E., Melton, L. J., O’Fallon, W. M., & Riggs, B. L. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90878-1 · Cited by 658
Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R. R., & Ferrando, A. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.5.e820 · Cited by 608
Osteoporosis: Etiology, diagnosis, and management
(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80791-1 · Cited by 605
Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels
Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990) · Metabolism · doi:10.1016/0026-0495(90)90297-p · Cited by 567
Effects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study
Morley, J. E., Perry, H. M., Kaiser, F. E., Kraenzle, D., Jensen, J., Houston, K., Mattammal, M. B., & Perry, H. M. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb02049.x · Cited by 462
Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor.
Bellido, T., Jilka, R. L., Boyce, B. F., Girasole, G., Broxmeyer, H. E., Dalrymple, S. A., Murray, R., & Manolagas, S. C. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117995 · Cited by 429
Castrated Men Exhibit Bone Loss: Effect of Calcitonin Treatment on Biochemical Indices of Bone Remodeling*
Stepan, J. J., Lachman, M., ZVĚŘINA, J., Pacovský, V., & Baylink, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 423

Show all 38 references

Sorted by citations

Items 101–200 of 792

Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health
Golds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Andropause
Vermeulen, A. (2000) · Maturitas · doi:10.1016/s0378-5122(99)00075-4 · Cited by 147
Gender differences in the cardiovascular effects of sex hormones
Vitale, C., Fini, M., Speziale, G., & Chierchia, S. L. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00817.x · Cited by 152
Metabolic Disorders and Male Hypogonadotropic Hypogonadism
Pivonello, R., Menafra, D., Riccio, E., Garifalos, F., Mazzella, M., de Angelis, C., & Colao, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00345 · Cited by 149
“In particular, one case-control study on 36 hypogonadal men, comprising 29 men with Hypo-H (20 with known cause and 9 idiopathic), and 7 men with Hyper-H, aged 22–68 years (median age 53 years), highlighted that TRT with 100mg intramuscular testosterone enanthate once per week for 18 months significantly decreased tot…”
Background
An Evidence-Based Narrative Review of Mechanisms of Resistance Exercise–Induced Human Skeletal Muscle Hypertrophy
LIM, C., NUNES, E. A., CURRIER, B. S., MCLEOD, J. C., THOMAS, A. C. Q., & PHILLIPS, S. M. (2022) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002929 · Cited by 142
“Testosterone is an androgenic hormone, and previous studies have been shown that exogenous administrations of testosterone in supraphysiological doses to healthy eugonadal men (81,82) and replacement doses to hypogonadal men (83,84) significantly increase muscle mass and lean body mass.”
Background
Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor‐α
Callewaert, F., Venken, K., Ophoff, J., Gendt, K. D., Torcasio, A., van Lenthe, H., Oosterwyck, H. V., Boonen, S., Bouillon, R., Verhoeven, G., et al. (2008) · The FASEB Journal · doi:10.1096/fj.08-113456 · Cited by 144
Attenuation of sarcopenia by dietary restriction in rhesus monkeys
Colman, R. J., Beasley, T. M., Allison, D. B., & Weindruch, R. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.6.556 · Cited by 141
Ageing in the musculoskeletal system
Roberts, S., Colombier, P., Sowman, A., Mennan, C., Rölfing, J. D., Guicheux, J., & Edwards, J. (2016) · Acta Orthopaedica · doi:10.1080/17453674.2016.1244750 · Cited by 149
“In men, low levels of androgens also cause increased bone remodeling and net bone loss (Daniell 1997, Katznelson et al. 1996), attributed in part to reduced levels of estrogen, which is derived from aromatization of testosterone (Falahati-Nini et al. 2000).”
Background
Testosterone Treatment and Fractures in Men with Hypogonadism
Snyder, P. J., Bauer, D. C., Ellenberg, S. S., Cauley, J. A., Buhr, K. A., Bhasin, S., Miller, M. G., Khan, N., Li, X., & Nissen, S. E. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308836 · Cited by 147
Bone Safety During the First Ten Years of Gender-Affirming Hormonal Treatment in Transwomen and Transmen
Wiepjes, C. M., de Jongh, R. T., de Blok, C. J. M., Vlot, M. C., Lips, P. T. A. M., Twisk, J. W. R., & den Heijer, M. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3612 · Cited by 141
“In transwomen with higher estradiol concentrations during HT an increase in LS BMD was found, whereas low estradiol concentrations were associated with a decrease in LS BMD. Testosterone concentrations were suppressed in the majority of the population and were not associated with the change in LS BMD. LH concentration…”
BackgroundInfluential
Hypogonadism and androgen replacement therapy in elderly men
Basaria, S. S., & Dobs, A. S. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00663-5 · Cited by 136
The structural basis of bone fragility in men
Seeman, E. (1999) · Bone · doi:10.1016/s8756-3282(99)00117-9 · Cited by 136
Androgen effects on bone metabolism: recent progress and controversies
Hofbauer, L. C., & Khosla, S. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400271 · Cited by 135
Testosterone Supplementation in Older Men: A Rational Idea Whose Time Has Not Yet Come
Bhasin, S., & Buckwalter, J. G. (2001) · Journal of Andrology · doi:10.1002/j.1939-4640.2001.tb02570.x · Cited by 136
Leydig cell stem cells: Identification, proliferation and differentiation
Chen, H., Wang, Y., Ge, R., & Zirkin, B. R. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.10.010 · Cited by 136
“These changes can be partially overcome by exogenous testosterone administration (Katznelson et al., 1996; Wang et al., 1996; Steidle et al., 2003; Page et al., 2005; Seftel et al., 2015).”
Background
Obesity, low testosterone levels and erectile dysfunction
Diaz‐Arjonilla, M., Schwarcz, M. G., Swerdloff, R. S., & Wang, C. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.42 · Cited by 134
Regulation of Myogenic Differentiation by Androgens: Cross Talk between Androgen Receptor/ β-Catenin and Follistatin/Transforming Growth Factor-β Signaling Pathways
Singh, R., Bhasin, S., Braga, M., Artaza, J. N., Pervin, S., Taylor, W. E., Krishnan, V., Sinha, S. K., Rajavashisth, T. B., & Jasuja, R. (2008) · Endocrinology · doi:10.1210/en.2008-0858 · Cited by 131
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Differential effects on bone of estrogen receptor α and androgen receptor activation in orchidectomized adult male mice
Movérare, S., Venken, K., Eriksson, A.-L., Andersson, N., Skrtic, S., Wergedal, J. E., Mohan, S., Salmon, P., Bouillon, R., Gustafsson, J.-Α., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2233084100 · Cited by 131
I. Introduction
Bhasin, S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5060-1 · Cited by 127
Transdermal Testosterone Administration in Women with Acquired Immunodeficiency Syndrome Wasting: A Pilot Study
Miller, K. K., Corcoran, C. P., Armstrong, C. A., Caramelli, K. E., Anderson, E. J., Cotton, D. J., Basgoz, N. O., Hirschhorn, L. R., TUOMALA, R. E., Schoenfeld, D., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5051 · Cited by 136
Self-citation
Testosterone Treatment in Adolescents with Delayed Puberty: Changes in Body Composition, Protein, Fat, and Glucose Metabolism1
Arslanian, S. A., & Suprasongsin, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.10.4293 · Cited by 128
Osteoporosis in men
Ebeling, P. R. (2013) · The biomedical & life sciences collection. · doi:10.1097/bor.0b013e328362164d · Cited by 131
Cardiovascular Aspects of Sexual Medicine
Jackson, G., Montorsi, P., Adams, M. A., Anis, T. H., El‐Sakka, A. I., Miner, M. M., Vlachopoulos, C. V., & Kim, E. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01779.x · Cited by 126
Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial
Basaria, S., Travison, T. G., Alford, D., Knapp, P. E., Teeter, K., Cahalan, C., Eder, R., Lakshman, K., Bachman, E., Mensing, G., et al. (2015) · Pain · doi:10.1097/01.j.pain.0000460308.86819.aa · Cited by 125
“Testosterone deficiency is associated with a decrease in lean mass and an increase in fat mass, a phenotype associated with reduced muscle strength and function.(6,24) Although effects of testosterone therapy on body composition are well established in other patient populations, it had not been studied in men with opi…”
Background
Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice
Axell, A.-M., MacLean, H. E., Plant, D. R., Harcourt, L. J., Davis, J. A., Jimenez, M., Handelsman, D. J., Lynch, G. S., & Zajac, J. D. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00058.2006 · Cited by 125
“Testosterone replacement therapy has been effectively used to counteract loss of lean body mass in hypogonadal men (4, 11, 32), older men with normal or low serum testosterone (21, 54), and HIV-infected men with low serum testosterone (2).”
Background
Osteoporosis in Men
Amin, S., & Felson, D. T. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70186-1 · Cited by 123
Androgens and the control of skeletal muscle protein synthesis
Sheffield‐Moore, M. (2000) · Annals of Medicine · doi:10.3109/07853890008998825 · Cited by 123
Androgen Signaling in Myocytes Contributes to the Maintenance of Muscle Mass and Fiber Type Regulation But Not to Muscle Strength or Fatigue
Ophoff, J., Proeyen, K. V., Callewaert, F., Gendt, K. D., Bock, K. D., Bosch, A. V., Verhoeven, G., Hespel, P., & Vanderschueren, D. (2009) · Endocrinology · doi:10.1210/en.2008-1509 · Cited by 123
Alendronate Treatment of Established Primary Osteoporosis in Men: Results of a 2-Year Prospective Study
Ringe, J. D., Faber, H., & Dorst, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7988 · Cited by 125
Role of Hormones in the Pathogenesis and Management of Sarcopenia
Kamel, H. K., Maas, D. L., & Duthie, E. H. (2002) · Drugs & Aging · doi:10.2165/00002512-200219110-00004 · Cited by 116
Androgen Replacement Therapy
Gooren, L. J., & Bunck, M. C. M. (2004) · Drugs · doi:10.2165/00003495-200464170-00002 · Cited by 118
Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age
Snyder, P. J., Peachey, H., Berlin, J. A., Rader, D. J., Usher, D. C., Loh, L., Hannoush, P., Dlewati, A., Holmes, J. H., Santanna, J., et al. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00813-0 · Cited by 116
Androgen Deficiency in Women with Hypopituitarism1
Miller, K. K., Sesmilo, G., Schiller, A., Schoenfeld, D., Burton, S., & Klibanski, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7246 · Cited by 117
“T EFFECTS OF androgen deficiency in men are well established and include osteopenia (1), an increase in fat mass (1), and a decrease in libido (2).”
BackgroundSelf-citation
Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy
Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., & Shalet, S. M. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01297.x · Cited by 115
“Fax: 0161 4463772; E-mail: Mmassey@picr.man.ac.uk 1986; Finkelstein et al., 1987), changes in body composition (Katznelson et al., 1996; Katznelson et al., 1998), increased fatigue, sexual dysfunction and alterations in mood (Burris et al., 1992).”
BackgroundInfluential
MALE HORMONE REPLACEMENT THERAPY INCLUDING “ANDROPAUSE”
Tenover, J. L. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70050-5 · Cited by 114
Treatment Strategies for Sarcopenia and Frailty
Rolland, Y., Dupuy, C., van Kan, G. A., Guyonnet, S., & Vellas, B. J. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.02.008 · Cited by 121
The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men
Snyder, P. J., Ellenberg, S. S., Cunningham, G. R., Matsumoto, A. M., Bhasin, S., Barrett-Connor, E. L., Gill, T. M., Farrar, J. T., Cella, D. F., Rosen, R. C., et al. (2014) · Clinical Trials · doi:10.1177/1740774514524032 · Cited by 116
“A prior study showed that testosterone increased volumetric bone mineral density by 9% (standard error 3%) in 1 year [46].”
Method
Testosterone Supplementation for Aging-Associated Sarcopenia
Bhasin, S. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.11.m1002 · Cited by 115
“Several studies (Bhasin et al. 1997; Brodsky et al. 1996; Katznelson et al. 1996; Wang et al. 2000; Snyder et al. 2000) have demonstrated that testosterone replacement of young, hypo gonadal men increases fat-free mass.”
BackgroundResult
Seasonal Variation of Testosterone and Waist to Hip Ratio in Men: The Tromsø Study
Svartberg, J. B., Jorde, R., Sundsfjord, J., Bønaa, K. H., & Barrett-Connor, E. L. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021878 · Cited by 114
A Lower Dosage Levonorgestrel and Testosterone Combination Effectively Suppresses Spermatogenesis and Circulating Gonadotropin Levels with Fewer Metabolic Effects Than Higher Dosage Combinations
Anawalt, B. D., Bebb, R. A., Bremner, W. J., & Matsumoto, A. M. (1999) · Journal of Andrology · doi:10.1002/j.1939-4640.1999.tb02535.x · Cited by 113
Cross-sex pattern of bone mineral density in early onset gender identity disorder
Haraldsen, I. R., Haug, E., Falch, J., Egeland, T., & Opjordsmoen, S. (2007) · Hormones and Behavior · doi:10.1016/j.yhbeh.2007.05.012 · Cited by 113
“Conversely, testosterone substitution increases BMD in cases of male hypogonadism (Katznelson et al., 1996), possibly by stimulating osteoblast proliferation and differentiation, thereby increasing matrix production and mineralization (Kasperk et al., 1989, 1997; Vanderschueren and Bouillon, 1995).”
Background
Myocytic androgen receptor controls the strength but not the mass of limb muscles
Chambon, C., Duteil, D., Vignaud, A., Ferry, A., Messaddeq, N., Malivindi, R., Kato, S., Chambon, P., & METZGER, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009536107 · Cited by 111
Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction
Traish, A. M., Feeley, R. J., & Guay, A. T. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07305.x · Cited by 115
Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men
Auyeung, T. W., Lee, J. S. W., Kwok, T. C. Y., Leung, J. C. S., Ohlsson, C., Vandenput, L., Leung, P., & Woo, J. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0952 · Cited by 109
ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: Scientific background and rationale
Lunenfeld, B., Saad, F., & Hoesl, C. E. (2005) · The Aging Male · doi:10.1080/13685530500163416 · Cited by 108
Male rodent model of age-related bone loss in men
Wang, L., Banu, J., McMahan, C. A., et al. (2001) · Bone · doi:10.1016/s8756-3282(01)00483-5 · Cited by 107
Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review
Shabsigh, R., Crawford, E. D., Nehra, A. X., & Slawin, K. M. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.31 · Cited by 106
The metabolic syndrome in long-term cancer survivors, and important target for secondary preventive measures
Nuver, J., Smit, A. J., Postma, A., Sleijfer, D. T., & Gietema, J. A. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00038-5 · Cited by 105
Sexually dimorphic effect of aging on skeletal muscle protein synthesis
Smith, G. I., Reeds, D. N., Hall, A. M., Chambers, K. T., Finck, B. N., & Mittendorfer, B. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-11 · Cited by 105
“Hypoandrogenemia is associated with a reduced lean body mass [14] and treatment with testosterone increases the muscle protein synthesis rate [15-20].”
Background
Normal bone mineral content but unfavourable muscle/fat ratio in Klinefelter syndrome
Aksglæde, L., Mølgaard, C., Skakkebæk, N. E., & Juul, A. (2007) · Archives of Disease in Childhood · doi:10.1136/adc.2007.120675 · Cited by 107
“Testosterone deficiency in otherwise healthy adult males is associated with a significant decrease in bone mineral density (BMD) and alterations in body composition.(4) 5 Accordingly, it is well established that patients with hypogonadism due to Klinefelter syndrome (KS) have a high risk of developing ostopenia or eve…”
Background
Gender differences in protein metabolism
Tipton, K. D. (2001) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200111000-00005 · Cited by 107
Testosterone Administration in Women with Anorexia Nervosa
Miller, K. K., Grieco, K. A., & Klibanski, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1181 · Cited by 108
Self-citation
The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism
Mohamed, O., Freundlich, R. E., Dakik, H. K., Grober, E. D., Najari, B. B., Lipshultz, L. I., & Khera, M. (2009) · International Journal of Impotence Research · doi:10.1038/ijir.2009.35 · Cited by 104
The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting
Carson, J. A., Hardee, J. P., & VanderVeen, B. N. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.11.005 · Cited by 109
Hypogonadism and diabetes
Betancourt-Albrecht, M., & Cunningham, G. R. (2003) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901031 · Cited by 102
Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma
Zhao, C., Maricic, M. J., Nguyen, P. L., Ahmann, F. R., Bruhn, R. L., & Dalkin, B. L. (2002) · Cancer · doi:10.1002/cncr.10967 · Cited by 102
Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study
Londen, G. J. V., Levy, M. E., Perera, S., Nelson, J. B., & Greenspan, S. L. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.06.006 · Cited by 101
“Androgen replacement in men with acquired hypogonadism reverses these changes [16].”
Background
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities
Cooper, G. D., Pickavance, L. C., Wilding, J. P. H., Harrold, J. A., Halford, J. C. G., & Goudie, A. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106069637 · Cited by 102
Gonadal steroids and energy homeostasis in the leptin era
Mystkowski, P., & Schwartz, M. W. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00458-5 · Cited by 98
Osteoporosis in Men
Ebeling, P. R. (1998) · Drugs & Aging · doi:10.2165/00002512-199813060-00002 · Cited by 98
“[60,61] Body fat and biochemical bone turnover markers decreased, while lean muscle mass increased with testosterone therapy.”
Background
Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo‐controlled trial
Hoyos, C. M., Killick, R., Yee, B. J., Grunstein, R. R., & Liu, P. Y. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04413.x · Cited by 118
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Faris, J. E., & Smith, M. R. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283391fd1 · Cited by 99
The Male Athlete Triad—A Consensus Statement From the Female and Male Athlete Triad Coalition Part II: Diagnosis, Treatment, and Return-To-Play
Fredericson, M., Kussman, A. L., Misra, M., Barrack, M. T., Souza, M. J. D., Kraus, E., Koltun, K. J., Williams, N. I., Joy, E. A., & Nattiv, A. (2021) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000948 · Cited by 109
Five Years of Growth Hormone Replacement Therapy in Adults: Age- and Gender-Related Changes in Isometric and Isokinetic Muscle Strength
Svensson, J., Sunnerhagen, K. S., & Johannsson, G. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020901 · Cited by 94
Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism.
Katznelson, L. J., Rosenthal, D. I., Rosol, M. S., Anderson, E. J., Hayden, D. L., Schoenfeld, D., & Klibanski, A. (1998) · American Journal of Roentgenology · doi:10.2214/ajr.170.2.9456958 · Cited by 95
Self-citation
Testosterone replacement therapy: for whom, when and how?
Tsametis, C. P., & Isidori, A. M. (2018) · Metabolism · doi:10.1016/j.metabol.2018.03.007 · Cited by 96
Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
Weickhardt, A. J., Rothman, M. S., Salian‐Mehta, S., Kiseljak‐Vassiliades, K., Oton, A. B., Doebele, R. C., Wierman, M. E., & Camidge, D. R. (2012) · Cancer · doi:10.1002/cncr.27450 · Cited by 92
“Chemo cycles: Mean [range] 19 [6-48] 9 [2-38]”
Current and Future Pharmacologic Treatment of Sarcopenia
Rolland, Y., Onder, G., Morley, J. E., Guyonnet, S., van Kan, G. A., & Vellas, B. J. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.03.008 · Cited by 95
Androgens in male senescence
Kaufman, J., & Vermeulen, A. (1998) · Springer eBooks · doi:10.1007/978-3-642-72185-4_16 · Cited by 92
Effects of Androgen Therapy on Adipose Tissue and Metabolism in Older Men
Schroeder, E. T., Zheng, L., Ong, M. D., Martinez, C., Flores, C., Stewart, Y., Azen, C. G., & Sattler, F. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0784 · Cited by 93
The many faces of testosterone
Bain, J. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s1417 · Cited by 90
“Although treatment with testosterone in hypogonadal men increases bone mineral density (Katznelson et al 1996), it has not yet been established that this results in a reduction in fracture rate.”
Sex steroids and the male skeleton: a tale of two hormones
Callewaert, F., Boonen, S., & Vanderschueren, D. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.09.002 · Cited by 93
Alendronate Treatment in Men With Primary Osteoporosis: A Three-Year Longitudinal Study
Gonnelli, S., Cepollaro, C., Montagnani, A., et al. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-1085-7 · Cited by 91
“Until 2 years ago, there were no therapies approved for men with primary osteoporosis; indeed, testosterone had been shown to increase BMD in hypogonadal men, but not in men with normal testosterone serum levels [7, 8].”
Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone
Zborowski, J. V., Cauley, J. A., Talbott, E. O., Guzick, D. S., & Winters, S. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6902 · Cited by 89
Risks Versus Benefits of Testosterone Therapy in Elderly Men
Basaria, S. S., & Dobs, A. S. (1999) · Drugs & Aging · doi:10.2165/00002512-199915020-00006 · Cited by 90
“[67] Bone specific al-”
Background
Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men
Christmas, C., O'Connor, K. G., Harman, S. M., Tobin, J. D., Münzer, T., Bellantoni, M. F., Clair, C. S., Pabst, K. M., Sorkin, J. D., & Blackman, M. R. (2002) · The Journals of Gerontology Series A · doi:10.1093/gerona/57.1.m12 · Cited by 90
“Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.”
Background
Osteopenia in Eugonadal Men with Acquired Immune Deficiency Syndrome Wasting Syndrome1
Fairfield, W. P., Finkelstein, J. S., Klibanski, A., & Grinspoon, S. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7515 · Cited by 89
“infected men with both congenital and acquired hypogonadism (9, 10).”
BackgroundSelf-citation
Cardiovascular Issues in Hypogonadism and Testosterone Therapy
Shabsigh, R., Katz, M. H., Yan, G., & Makhsida, N. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.10.009 · Cited by 89
Effects of Transdermal Testosterone on Lipids and Vascular Reactivity in Older Men With Low Bioavailable Testosterone Levels
Kenny, R. A., Prestwood, K. M., Gruman, C., Fabregas, G., Biskup, B., & Mansoor, G. (2002) · The Journals of Gerontology Series A · doi:10.1093/gerona/57.7.m460 · Cited by 89
An Aged Rat Model of Partial Androgen Deficiency: Prevention of Both Loss of Bone and Lean Body Mass by Low-Dose Androgen Replacement1
Vanderschueren, D., Vandenput, L., Boonen, S., Van Herck, E., Swinnen, J. V., & Bouillon, R. (2000) · Endocrinology · doi:10.1210/endo.141.5.7472 · Cited by 88
Bone Mineral Density and Quantitative Ultrasound Parameters in Patients with Klinefelter's Syndrome after Long-Term Testosterone Substitution
van den Bergh, J. P., Hermus, A. R. M. M., Spruyt, A. I., Sweep, F. C. G. J., Corstens, F. H. M., & SMALS, A. G. H. (2001) · Osteoporosis International · doi:10.1007/s001980170158 · Cited by 88
Androgens and the Regulation of Adiposity and Body Fat Distribution in Humans
Tchernof, A., Brochu, D., Maltais‐Payette, I., Mansour, M. F., Marchand, G. B., Carreau, A., & Kapeluto, J. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170009 · Cited by 113
Testosterone and the aging male: To treat or not to treat?
Bain, J. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.009 · Cited by 84
Testosterone increases bone mineral density in female‐to‐male transsexuals: a case series of 15 subjects
Turner, A., Chen, T. C., Barber, T. W., Malabanan, A. O., Holick, M. F., & Tangpricha, V. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02125.x · Cited by 86
“Testosterone treatment of elderly men with hypogonadism increases BMD (Katznelson et al., 1996; Behre et al., 1997, 1999; Snyder et al., 1999; Amory et al., 2004).”
Background
Testosterone replacement therapy in older adult men
Tenover, J. L. (1999) · International Journal of Andrology · doi:10.1046/j.1365-2605.1999.00184.x · Cited by 84
OSTEOPOROSIS
Kenny, A. M., & Prestwood, K. M. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70157-5 · Cited by 83
Bone mineral density in people living with HIV: a narrative review of the literature
Kruger, M., & Nell, T. A. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0162-y · Cited by 87
“When androgen levels are low, it is associated with bone loss and increased bone remodelling in men [113, 114]; however, a reduction in oestrogen seems to play a key role in the age-related decrease of BMD [115, 116].”
Background
The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2
Saad, F., & Gooren, L. J. (2010) · Journal of Obesity · doi:10.1155/2011/471584 · Cited by 82
“So, apparently while androgens induce visceral fat accumulation, once fat has been stored in the visceral depot it does not need continued androgen stimulation as opposed to maintenance of bone and muscle mass, which are lower in men with adult onset hypogonadism than in eugonadal controls [13].”
Background
Musculoskeletal Disorders in Chronic Obstructive Pulmonary Disease
Cielen, N., Maes, K., & Gayan‐Ramirez, G. (2014) · BioMed Research International · doi:10.1155/2014/965764 · Cited by 86
Testosterone Deficiency and Replacement
Howell, S., & Shalet, S. M. (2001) · Hormone Research in Paediatrics · doi:10.1159/000048142 · Cited by 82
“demonstrated a 15p increase in fat-free mass and an 11p decrease in fat mass following 6 months’ treatment with testosterone cipionate 3 mg/kg every 2 weeks, and this was associated with a 56p increase in protein synthesis. Similar changes were seen following 18 months’ treatment with testosterone enanthate in a study…”
Background
The mutual dependence between bone and gonads
Karsenty, G. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0452 · Cited by 81
“…sexual dimorphism is mainly due to a stimulatory androgen action on periosteal bone formation in men, whereas an inhibitory estrogen-related action occurs in women (Bertelloni et al. 1995, Finkelstein et al. 1996, Katznelson et al. 1996, Seeman 2001, Venken et al. 2006, Kirmani et al. 2009).”
Background
Androstenedione Does Not Stimulate Muscle Protein Anabolism in Young Healthy Men1
Rasmussen, B. B., Volpi, E., Gore, D. C., & Wolfe, R. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6322 · Cited by 80
“2): phenylalanine entry into leg: Fin 5 CA 3 BF (1); phenylalanine exit from leg: Fout 5 CV 3 BF (2); net balance across the leg: NB 5 (CA 2 Cv) 3 BF (3); muscle inward transport: FM,A 5 {[(EM 2 EV)/(EA 2 EM)] 3 CV 1 CA} 3 BF (4); muscle outward transport: FV,M 5 {[(EM 2 EV)/(EA 2 EM)] 3 CV 1 CV} 3 BF (5); A-V shuntin…”
Effects of testosterone on body composition of the aging male
Mudali, S. (2004) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.01.004 · Cited by 77
In Vivo μMRI-Based Finite Element and Morphological Analyses of Tibial Trabecular Bone in Eugonadal and Hypogonadal Men Before and After Testosterone Treatment
Zhang, X. H., Liu, X. S., Vasilic, B., Wehrli, F. W., Benito, M., Rajapakse, C. S., Snyder, P. J., & Guo, X. E. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080405 · Cited by 79
“in the United States have osteoporosis, whereas the lifetime risk of osteoporotic fractures in men has been estimated to be 13–25%.((4,5)) Among men evaluated for osteoporosis, 5–30% have no apparent cause other than hypogonadism.”
Background
Effects of Testosterone Administration on Fat Distribution, Insulin Sensitivity, and Atherosclerosis Progression
Bhasin, S. (2003) · Clinical Infectious Diseases · doi:10.1086/375878 · Cited by 78
“[42] 22–69 TE or TC 100 mg/week for 18 months 7 2% increase by bioelectrical impedance 14 4% decrease in % body fat, 13 4% decrease in SC fat ND”
Background
Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance
Rana, K., Fam, B. C., Clarke, M. V., Pang, T. P. S., Zajac, J. D., & MacLean, H. E. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00584.2010 · Cited by 78
Androgen Effects on Adipose Tissue Architecture and Function in Nonhuman Primates
Varlamov, O., White, A. E., Carroll, J. M., Bethea, C. L., Reddy, A. P., Slayden, O. D., O’Rourke, R. W., & Roberts, C. T. (2012) · Endocrinology · doi:10.1210/en.2011-2111 · Cited by 74
Impact of obesity on hypogonadism in the andropause
TAN, R. S.-H., & Pu, S. J. (2002) · International Journal of Andrology · doi:10.1046/j.1365-2605.2002.00356.x · Cited by 76
Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study
Francomano, D., Bruzziches, R., Bárbaro, G., Lenzi, A., & Aversa, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0066-9 · Cited by 76
“between male obesity with lower plasma T levels [4] and other studies have shown that low T levels are predictive for the development of visceral obesity [5] with an increase of fat mass and a decrease in lean body mass compared to eugonadal men [6].”
Background

Authors: Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A.
Affiliations: Massachusetts General Hospital (US)
ORCID: Katznelson, L
Finkelstein, J S
Schoenfeld, D A
Rosenthal, D I
Anderson, E J
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 1996-12
Volume: 81
Issue: 12
Pages: 4358-4365
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jcem.81.12.8954042
OpenAlex: W1974568933
Semantic Scholar: 829db808d1847d263af6c33d3397743284ea9f83
Cited by: 791
References: 38
Citations by year: 2026: 2 · 2025: 9 · 2024: 12 · 2023: 13 · 2022: 16 · 2021: 15 · 2020: 15 · 2019: 14 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 24 · 2014: 17 · 2013: 29 · 2012: 35
FWCI: 19.42
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5f32dk008738-02)
National Institute of Diabetes and Digestive and Kidney Diseases (DK-08738)
National Center for Research Resources (RR 01066, M01RR001066)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords: testosterone replacement therapy, testosterone enanthate, bone mineral density, trabecular bone density, lean body mass, body composition, fat mass, central hypogonadism, hypergonadotropic hypogonadism, bone-specific alkaline phosphatase, urinary deoxypyridinoline, bone turnover markers, men's health, osteoporosis prevention
MeSH terms: Adult, Aged, Body Composition, Bone Development, Humans, Hypogonadism, Cholesterol, HDL, Longitudinal Studies, Male, Middle Aged, Parathyroid Hormone, Growth Hormone, Testosterone, Bone Density

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks